EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial

Anne-Sophie Homøe iD, Kasper Aanæs, Jens Even Tidemandsen, Haase Christiane Holbaek, Rubek Niclas, Samuelsen Grethe Badsberg, Larsen Bent Ivan Holmegaard, Vibeke Backer

International Forum of Allergy & Rhinology · 2025-07 · 15 (7) · 724-733

DOI: 10.1002/alr.23562 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 10.03.2025. Verfasst von Anne-Sophie Homøe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts patients’ quality of life (QoL). Standard treatments include nasal irrigations, nasal steroids, systemic corticosteroids, and functional endoscopic sinus surgery (FESS). Uncontrolled severe CRSwNP treated with monoclonal antibodies (biologic drugs) gain better disease control, although some residual symptoms may persist. Combining biologic therapy with FESS could potentially reduce residual symptoms faster and for a longer period. Therefore, we aim to compare the effectiveness of combined FESS and biologic therapy against biologics alone in patients with severe CRSwNP. Materials and Methods This randomised controlled trial (RCT) enrolled 58 patients with CRSwNP and type 2 inflammation who were randomly assigned to FESS or non‐FESS groups. All patients were treated with 100 mg of s.c. mepolizumab every 4 weeks for 6 months. Those in the FESS group underwent surgery 2 weeks after the first injection. Patients were assessed at baseline and after 6 months using the sino‐nasal outcome test‐22 (SNOT‐22), visual analog scale (VAS), nasal congestion score (NCS), and the smell identification test (16 sticks). Clinical evaluations were performed using rhinoscopy to identify nasal polyp scores (NPS).

Results

Both treatment groups significantly improved in terms of their SNOT‐22 scores after 6 months of treatment ( p < 0.001). There were not significant differences between the two groups ( p = 0.055). Patients with large NPS (6–8) improved significantly in terms of their SNOT‐22 scores when they underwent combined treatment (FESS and mepolizumab) compared with s.c. mepolizumab alone ( p < 0.05). They also exhibited improvements in ΔNPS ( p < 0.001), VAS CRS ( p = 0.074), and NCS reduction ( p < 0.001) after undergoing combined treatment compared with those who had mepolizumab alone.

Conclusion

Patients with large polyp scores experienced significant improvements in their QoL (SNOT‐22) and reduced NPS, NCS, and VAS CRS more when polyp burden was reduced with FESS in association with mepolizumab treatment compared to those treated with mepolizumab alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsRhinitisAntibodies, Monoclonal, HumanizedParanasal SinusesHumansFemaleMaleMiddle AgedAdultEndoscopyChronic DiseaseTreatment OutcomeCombined Modality TherapyQuality of LifeAged

Stichwörter der Autor:innen

biologicschronic sinusitischronic sinusitis with nasal polypsmepolizumabmonoclonal antibodiesparanasal sinus diseasesinus surgery

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Department of Otorhinolaryngology, North Zealand Hospital, Hillerød, Denmark.
  • Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Køge, Denmark.

ORCID-Profile: Anne-Sophie Homøe

Förderung

  • GlaxoSmithKline

Zitieren

APA

Homøe, A. S., Aanæs, K., Tidemandsen, J. E., Holbaek, H. C., Niclas, R., Badsberg, S. G., Holmegaard, L. B. I., & Backer, V. (2025). Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial. International Forum of Allergy & Rhinology, 15(7), 724-733. https://doi.org/10.1002/alr.23562

Vancouver

Homøe AS, Aanæs K, Tidemandsen JE, Holbaek HC, Niclas R, Badsberg SG, et al. Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial. International Forum of Allergy & Rhinology. 2025;15(7):724-733. doi:10.1002/alr.23562

BibTeX
@article{Home2025,
  author = {Homøe, Anne-Sophie and Aanæs, Kasper and Tidemandsen, Jens Even and Holbaek, Haase Christiane and Niclas, Rubek and Badsberg, Samuelsen Grethe and Holmegaard, Larsen Bent Ivan and Backer, Vibeke},
  title = {Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {724--733},
  doi = {10.1002/alr.23562}
}
Kostenlos starten →